US Pharma MarketingVertex drops mRNA cystic fibrosis program over 'tolerability' issues
Vertex has dropped VX-522, the inhaled mRNA cystic fibrosis therapy it developed with Moderna, citing persistent tolerability issues tied to the lipid nanoparticle delivery system. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene…
Vertex Pharmaceuticals said it has dropped development of an mRNA-based cystic fibrosis therapy after facing challenges similar to those that have troubled other parts of the field in delivering the genetic medicine.
The Boston-based company ...
Source: Endpoints News